U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 3C30H35ClN7O10S2.4C7H7O3S.O4S.3H.H2O
Molecular Weight 3061.545
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of CEFIDEROCOL SULFATE TOSYLATE

SMILES

[H+].[H+].[H+].O.[O-]S([O-])(=O)=O.CC1=CC=C(C=C1)S([O-])(=O)=O.CC2=CC=C(C=C2)S([O-])(=O)=O.CC3=CC=C(C=C3)S([O-])(=O)=O.CC4=CC=C(C=C4)S([O-])(=O)=O.[H][C@]56SCC(C[N+]8(CCNC(=O)C7=C(Cl)C(O)=C(O)C=C7)CCCC8)=C(N5C(=O)[C@H]6NC(=O)C(=N/OC(C)(C)C(O)=O)\C9=CSC(N)=N9)C(O)=O.[H][C@]%10%11SCC(C[N+]%13(CCNC(=O)C%12=C(Cl)C(O)=C(O)C=C%12)CCCC%13)=C(N%10C(=O)[C@H]%11NC(=O)C(=N/OC(C)(C)C(O)=O)\C%14=CSC(N)=N%14)C(O)=O.[H][C@]%15%16SCC(C[N+]%18(CCNC(=O)C%17=C(Cl)C(O)=C(O)C=C%17)CCCC%18)=C(N%15C(=O)[C@H]%16NC(=O)C(=N/OC(C)(C)C(O)=O)\C%19=CSC(N)=N%19)C(O)=O

InChI

InChIKey=QNMVZYPDWLKAJC-RXVBEKIDSA-N
InChI=1S/3C30H34ClN7O10S2.4C7H8O3S.H2O4S.H2O/c3*1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31;4*1-6-2-4-7(5-3-6)11(8,9)10;1-5(2,3)4;/h3*5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47);4*2-5H,1H3,(H,8,9,10);(H2,1,2,3,4);1H2/t3*20-,26-;;;;;;/m111....../s1

HIDE SMILES / InChI

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H7O3S
Molecular Weight 171.194
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C30H35ClN7O10S2
Molecular Weight 753.223
Charge 1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula O4S
Molecular Weight 96.063
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
138 mg/L
2 g 3 times / day multiple, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
89.7 mg/L
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1184 mg × h/L
2 g 3 times / day multiple, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
386 mg × h/mL
2 g single, intravenous
dose: 2 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
CEFIDEROCOL unknown
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Disc. AE: Diarrhea, Drug hypersensitivity...
Other AEs: Diarrhea, Infusion site reactions...
AEs leading to
discontinuation/dose reduction:
Diarrhea (0.3%)
Drug hypersensitivity (0.3%)
Hepatic enzymes increased (0.3%)
Death (grade 5, 0.3%)
Other AEs:
Diarrhea (4%)
Infusion site reactions (4%)
Constipation (3%)
Rash (3%)
Candidiasis (2%)
Cough (2%)
Elevated liver enzymes (2%)
Headache (2%)
Hypokalemia (2%)
Nausea (2%)
Vomiting (2%)
Thrombocytosis (<2%)
Congestive heart failure (<2%)
Bradycardia (<2%)
Atrial fibrillation (<2%)
Abdominal pain (<2%)
Dry mouth (<2%)
Stomatitis (<2%)
Pyrexia (<2%)
Peripheral edema (<2%)
Cholelithiasis (<2%)
Cholecystitis (<2%)
Gallbladder pain (<2%)
Drug hypersensitivity (<2%)
Clostridium difficile infection (<2%)
Prothrombin time prolonged (<2%)
Red blood cells urine positive (<2%)
Creatine phosphokinase increased (<2%)
Decreased appetite (<2%)
Hypocalcemia (<2%)
Fluid overload (<2%)
Dysgeusia (<2%)
Seizure (<2%)
Dyspnea (<2%)
Pleural effusion (<2%)
Pruritis (<2%)
Insomnia (<2%)
Restlessness (<2%)
Sources:
1 g 1 times / day single, intravenous
Dose: 1 g, 1 times / day
Route: intravenous
Route: single
Dose: 1 g, 1 times / day
Sources:
unhealthy, mean age 60.1 years
n = 8
Health Status: unhealthy
Condition: Gram-Negative Bacterial Infections
Age Group: mean age 60.1 years
Sex: M+F
Population Size: 8
Sources:
Disc. AE: Urticaria...
AEs leading to
discontinuation/dose reduction:
Urticaria (12.5%)
Sources:
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Disc. AE: Death, Elevated liver enzymes...
Other AEs: Elevated liver enzymes, Hypokalemia...
AEs leading to
discontinuation/dose reduction:
Death (grade 5, 26.4%)
Elevated liver enzymes
Other AEs:
Elevated liver enzymes (16%)
Hypokalemia (11%)
Diarrhea (9%)
Hypomagnesemia (5%)
Atrial fibrillation (5%)
Thrombocytopenia (<4%)
Thrombocytosis (<4%)
Myocardial infarction (<4%)
Atrial flutter (<4%)
Nausea (<4%)
Vomiting (<4%)
Abdominal pain (<4%)
Cholecystitis (<4%)
Cholestasis (<4%)
Clostridium difficile infection (<4%)
Oral candidiasis (<4%)
Prothrombin time prolonged (<4%)
Activated partial thromboplastin time (<4%)
Hypocalcemia (<4%)
Hyperkalemia (<4%)
Seizure (<4%)
Acute interstitial nephritis (<4%)
Cough (<4%)
Rash (<4%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Drug hypersensitivity 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Hepatic enzymes increased 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Candidiasis 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Cough 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Elevated liver enzymes 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Headache 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Hypokalemia 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Nausea 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Vomiting 2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Constipation 3%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Rash 3%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Diarrhea 4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Infusion site reactions 4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Abdominal pain <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Atrial fibrillation <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Bradycardia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Cholecystitis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Cholelithiasis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Clostridium difficile infection <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Congestive heart failure <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Creatine phosphokinase increased <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Decreased appetite <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Drug hypersensitivity <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Dry mouth <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Dysgeusia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Dyspnea <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Fluid overload <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Gallbladder pain <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Hypocalcemia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Insomnia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Peripheral edema <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Pleural effusion <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Prothrombin time prolonged <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Pruritis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Pyrexia <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Red blood cells urine positive <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Restlessness <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Seizure <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Stomatitis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Thrombocytosis <2%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Death grade 5, 0.3%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 18 to 93 years
n = 300
Health Status: unhealthy
Condition: Complicated Urinary Tract Infections
Age Group: 18 to 93 years
Sex: M+F
Population Size: 300
Sources:
Urticaria 12.5%
Disc. AE
1 g 1 times / day single, intravenous
Dose: 1 g, 1 times / day
Route: intravenous
Route: single
Dose: 1 g, 1 times / day
Sources:
unhealthy, mean age 60.1 years
n = 8
Health Status: unhealthy
Condition: Gram-Negative Bacterial Infections
Age Group: mean age 60.1 years
Sex: M+F
Population Size: 8
Sources:
Hypokalemia 11%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Elevated liver enzymes 16%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Atrial fibrillation 5%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Hypomagnesemia 5%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Diarrhea 9%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Abdominal pain <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Activated partial thromboplastin time <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Acute interstitial nephritis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Atrial flutter <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Cholecystitis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Cholestasis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Clostridium difficile infection <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Cough <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Hyperkalemia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Hypocalcemia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Myocardial infarction <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Nausea <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Oral candidiasis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Prothrombin time prolonged <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Rash <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Seizure <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Thrombocytopenia <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Thrombocytosis <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Vomiting <4%
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Elevated liver enzymes Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
Death grade 5, 26.4%
Disc. AE
2 g 3 times / day multiple, intravenous
Recommended
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, median age - 67 years
n = 148
Health Status: unhealthy
Condition: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Age Group: median age - 67 years
Sex: M+F
Population Size: 148
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
yes
no (co-administration study)
Comment: The results from a clinical drug-drug interaction study indicate that cefiderocol had no clinically meaningful effects on the PK of furosemide (substrate for OAT1 and OAT3), metformin (for OCT1, OCT2, and MATE2- K), and rosuvastatin (for OATP1B3).
Page: 64.0
Drug as victimTox targets

Tox targets

Substance Class Chemical
Created
by admin
on Thu Jul 06 20:24:38 UTC 2023
Edited
by admin
on Thu Jul 06 20:24:38 UTC 2023
Record UNII
TTP8LBP45D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFIDEROCOL SULFATE TOSYLATE
USAN  
Official Name English
S-649266D
Code English
CEFIDEROCOL TOSILATE SULFATE HYDRATE [JAN]
Common Name English
CEFIDEROCOL SULFATE TOSYLATE [MI]
Common Name English
FETROJA
Brand Name English
GSK-2696266D
Code English
CEFIDEROCOL SULFATE TOSYLATE [ORANGE BOOK]
Common Name English
CEFIDEROCOL SULFATE TOSYLATE [USAN]
Common Name English
PYRROLIDINIUM, 1-(((6R,7R)-7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-((1-CARBOXY-1-METHYLETHOXY)IMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-(2-((2-CHLORO-3,4-DIHYDROXYBENZOYL)AMINO)ETHYL)-, 4-METHYLBENZENESULFONATE SULF
Systematic Name English
Cefiderocol sulfate tosylate [WHO-DD]
Common Name English
CEFIDEROCOL TOSILATE SULFATE HYDRATE
Common Name English
GSK2696266D
Code English
Code System Code Type Description
RXCUI
2265863
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
USAN
EF-100
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
CAS
2135543-94-9
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
DRUG BANK
DBSALT002912
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
NCI_THESAURUS
C169832
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
FDA UNII
TTP8LBP45D
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
SMS_ID
100000175867
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
MERCK INDEX
M12179
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
DAILYMED
TTP8LBP45D
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
PUBCHEM
131666060
Created by admin on Thu Jul 06 20:24:38 UTC 2023 , Edited by admin on Thu Jul 06 20:24:38 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY